Any potential COVID-19 vaccine would have to clear a slew of scientific and bureaucratic hurdles in record time in order to be ready for distribution this fall. The drugmakers running the vaccine trials are likely making projections “based on how rapidly they’re accruing data,” Susan Ellenberg, PhD, interim chair of Biostatistics, Epidemiology and Informatics at Penn Medicine, said in an interview with ProPublica. Ellenberg also commented on the vaccine approval process in a MedScape story.
top of page
bottom of page